Join to view full profile
450 Brookline AveDana 2127Boston, MA 02215
Phone+1 617-582-9030
Fax+1 212-263-6727
Dr. Ott is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2005 - 2008- NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2007
Ludwig Maximilian University of Munich Faculty of MedicineClass of 1996
Certifications & Licensure
FL State Medical License 2022 - Present
MA State Medical License 2012 - 2026
NY State Medical License 2008 - 2013
OH State Medical License 2002 - 2005
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2013, 2015, 2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013, 2015, 2017
- CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2013, 2015, 2017
Clinical Trials
- A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
- A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors Start of enrollment: 2013 Nov 15
- Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma
Publications & Presentations
PubMed
- Single-nucleus multimodal spatial transcriptomics reveals spatial colocalization of neoantigen-expressing tumor cells and cognate T cells.Adi Nagler, Amit Sud, Jack Y Ghannam, Lucas Pomerance, Camila Robles-Oteiza
Nature Biotechnology. 2026-07-22 - Tertiary lymphoid structures harbour stem-like tumour-specific T cells.Alexander B Afeyan, Adi Nagler, Chloe R Tu, Gabriel Roberti De Oliveira, Berkay Simsek
Nature. 2026-07-22 - Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.Susan M Swetter, Douglas Johnson, Mark R Albertini, Christopher A Barker, Sarah Bateni
Journal of the National Comprehensive Cancer Network. 2026-06-01
Journal Articles
- Pan-Tumor Genomic Biomarkers for PD-1 Checkpoint Blockade–Based ImmunotherapyJonathan Cheng, Patrick A Ott, Elizabeth R Plimack, Antoni Ribas, Andrew Joe, Science Magazine
- Pembrolizumab for Advanced Prostate Adenocarcinoma: Findings of the KEYNOTE-028 StudyM Gould, P Yang, P A Ott, Annals of Oncology
- A Cloning and Expression System to Probe T Cell Receptor Specificity and Assess Functional Avidity to NeoantigensWilliam J Lane, Patrick A Ott, Catherine J Wu, Donna E Leet, Blood
Press Mentions
HMN 2025: How Modified Customized Cancer Vaccine Generates {Powerful} Immune ResponseJuly 12th, 2025- Modified Personalized Cancer Vaccine Generates Powerful Immune ResponseJuly 10th, 2025
- Personalized Vaccine May Help Prevent Kidney Cancer RecurrenceFebruary 13th, 2025
Grant Support
- Dissecting melanoma-specific clonal T cell populations in patients treated with neoadjuvant immune checkpoint inhibition and personal neoantigen peptide vaccines.DANA-FARBER CANCER INST2018–2031
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
